Table 5. Test performance of LR2, Simple Rules and RMI in pre- and postmenopausal patients using a meta-analysis approach on centre-specific data.

Diagnostic method	AUC (95% CI)	Sens, % (95% CI)	Spec, % (95% CI)
Premenopausal patients
LR2	0.908 (0.886–0.926)	85 (78–90)	82 (77–87)
SRMal		95 (91–97)	77 (70–83)
SR+SA		92 (86–95)	91 (87–94)
RMI	0.867 (0.837–0.892)	53 (45–61)	94 (92–96)
Postmenopausal patients
LR2	0.897 (0.872–0.917)	94 (92–96)	65 (58–71)
SRMal		96 (93–97)	66 (59–73)
SR+SA		93 (90–95)	83 (78–87)
RMI	0.850 (0.805–0.887)	78 (72–83)	81 (76–85)

Abbreviations: AUC=area under the receiver-operating characteristics curve; CI=confidence interval; IOTA=international ovarian tumour analysis; LR2=logistic regression model 2; RMI=Risk of Malignancy Index; RMI-1=risk of malignancy index-1; Sens=sensitivity; Spec=specificity; SRMal=a one-step strategy using the IOTA Simple Rules as a first stage test and classifying tumours where the simple rules yield an inconclusive result as malignant; SR+SA=a two-stage strategy using the IOTA simple rules as a first stage test and using subjective assessment for those tumours where the simple rules yield an inconclusive result.